Best in Biotech 11 Jan 2021 The 21 European Biotech Companies To Watch in 2021 …In 2020, results of a phase III trial showed that its lead candidate efgartigimod improved motor symptoms of patients living with myasthenia gravis, a rare, chronic autoimmune disease. The company… January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
In Depth 22 May 2024 The undruggable cancer target: KRAS inhibitors move ahead in the clinic …a report by Cancer.Net. KRAS inhibitors battle it out in the clinical arena KRAS inhibitors head-to-head: adagrasib versus sotorasib Like BridgeBio, other biopharmas are ushering their candidates towards the clinic…. May 22, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? …a clinical trial halt for a CAR-T candidate. Belgian pharmaceutical Galapagos paused the enrollment of patients in a phase 1/2 trial that began last year. The study was designed to… August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2025 First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? …of its antibiotic zosurabalpin into phase 3 trials. The candidate will “address the challenge of increasing antibiotic resistance,” according to Michael Lobritz, global head of Infectious Diseases, Roche Pharma Research… June 9, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Jul 2025 New horizons in sickle cell disease treatment: Promising therapies on the way …the rest of their lives. With Casgevy and Lyfgenia opening the doors of possibility, there are now several other candidates in clinical trials hoping to find their way to approval…. July 17, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 14 Oct 2025 Prader Willi syndrome: five much-anticipated therapies poised for approval …condition. The small molecule ARD-101 is an oral candidate that targets the gut, specifically bitter-taste receptors present in the intestine. This stimulates the release of a hormone called cholecystokinin, which… October 14, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2024 From LSD to healing minds: Where are we standing in psychedelic drug development? …of the quality of the candidate itself to recoup their investment,” explained Qi. Qi describes the second phase as when companies such as Cybin were using deuterated psychedelic molecules, the… March 13, 2024 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations? …numbers of people smoking, rising air pollution and an aging population. Mereo could be onto a winner, with the candidate potentially filling a gap in the market, with no approved… December 11, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2020 Universal Flu Vaccines Yield Second Clinical Failure This Year …This was BiondVax’s only clinical candidate and investors reacted poorly, sending the stock into free fall. Back in June, BiondVax reported that the vaccine had shown promise against flu by… October 29, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has… November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 4 Oct 2023 CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off? …drug (IND) status for its drug candidate AB-201, a CAR-NK therapy for the treatment of solid tumors. AB-201 became the first CAR-NK therapy candidate to tend to HER2-positive cancer indications,… October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs,… February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email